Croatian generic drugmaker Pliva, at the centre of a bid battle, said on Friday U.S. regulators had given a green light to three of its drugs after problems were fixed at production facilities in Zagreb. BioSpace (http://www.biospace.com/news_story.aspx?StoryId=23611)